Company news

Racura Oncology Ltd news in 2025

Racura Oncology Ltd's news releases, calls and decks from 2025, newest first.

View company

Racura Oncology Appoints BDD for HARNESS-1 Trial

December 23, 2025

Race Oncology Completes $3.22m Private Placement

December 8, 2025

Race Receives $2.8m RD Tax Refund

November 26, 2025

HARNESS1 Lung Cancer Trial Receives Human Ethics Approval

November 25, 2025

Race Clinical Program Update

November 16, 2025

September 2025 Quarterly Activity Report and Appendix 4C

October 30, 2025

Race Presents Mechanism of Action Data at ESMO 2025

October 19, 2025

Discovery of the Anticancer Mechanism of (EE)-bisantrene

October 1, 2025

RC220 IND Approval from Korean MFDS

September 23, 2025

Race Breakthrough Composition of Matter IP Discovery

September 15, 2025

First Hong Kong Site Activated for RC220 Trial

September 1, 2025

Appendix 4E & Annual Report

August 26, 2025

June 2025 Quarterly Activity Report and Appendix 4C

July 22, 2025

RC220 Human Ethics Approvals Received in Hong Kong

July 9, 2025

First Patient Safely Combine Dosed in Phase 1 RC220 Trial

June 18, 2025

First Patient Dosed Safely in RC220 Phase 1 Trial

April 30, 2025

March 2025 Quarterly Activity Report and Appendix 4C

April 22, 2025

Enrolment Opened at Second Site for RC220 Phase 1 Trial

April 21, 2025

RC220 Phase 1 Trial Opens for Patient Enrolment

April 2, 2025

Race Initiates First AU Site for Phase 1 Solid Tumour Trial

March 27, 2025

Ethics approval received for RC220 Phase 1 Trial

March 13, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Race Signs Contract for Phase 1 Trial of RC220

March 4, 2025

Quarterly Activity Report and Appendix 4C

January 30, 2025

Decks in 2025